Humulin M3 (Mixture 3)

Humulin M3 (Mixture 3) is a prescription injectable solution that contains 100 U/mL of human insulin produced by recombinant DNA technology. It is supplied as a clear aqueous solution for subcutaneous administration and is classified as an antidiabetic agent used in the management of diabetes mellitus. It is marketed in the European Union and is intended for patients requiring a mixed‑action insulin profile to cover both basal and prandial glucose needs.

Humulin M3 is indicated for the treatment of diabetes mellitus where a combination of rapid and intermediate insulin action is desired. - Type 1 diabetes mellitus requiring basal and mealtime glucose control. - Type 2 diabetes mellitus inadequately controlled with diet, exercise, or oral agents alone. - Patients transitioning from separate regular and NPH insulin injections to a single mixed formulation. - Situations where a predictable insulin profile simplifies dosing schedules. - Individuals seeking fewer daily injections while maintaining adequate basal coverage. - Patients using a twice‑daily regimen who benefit from combined rapid‑acting and intermediate‑acting insulin.

Adverse reactions to Humulin M3 may vary in frequency and severity; they are typically categorized as common or serious. Common: - Hypoglycemia, which may manifest as sweating, tremor, hunger, dizziness, or confusion. - Injection‑site reactions such as redness, swelling, bruising, or itching at the administration site. - Lipodystrophy, including lipohypertrophy or lipoatrophy at sites of repeated injections. - Weight gain that can occur as glycemic control improves and caloric utilization changes. Serious: - Severe hypoglycemia that requires assistance from another person or medical intervention. - Allergic reactions ranging from mild urticaria to life‑threatening anaphylaxis. - Edema or fluid retention, particularly in patients with underlying cardiac, hepatic, or renal disease. - Persistent hyperglycemia suggesting possible insulin resistance, dosing error, or infection.

When prescribing Humulin M3, clinicians should consider several precautionary measures to minimize risks and ensure safe use. - Assess renal and hepatic function before initiating therapy, as impairment may affect insulin clearance. - Monitor blood glucose regularly to detect hypoglycemia or hyperglycemia early. - Adjust doses during periods of illness, stress, or changes in physical activity. - Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Avoid injecting into scarred, inflamed, or lipodystrophic tissue to reduce absorption variability. - Review concomitant medications that may potentiate or blunt insulin effects.

Humulin M3 can interact with other agents that influence glucose metabolism or insulin action; recognizing these interactions helps optimize therapy. Avoid: - Concurrent use of other rapid‑acting insulins or high‑dose sulfonylureas, which may precipitate severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, complicating detection and treatment. - Alcohol consumption in excess, which can cause unpredictable glucose fluctuations and increase hypoglycemia risk. Use with caution: - Oral antihyperglycemics (e.g., metformin, thiazolidinediones) that may require dose adjustments. - Corticosteroids or sympathomimetics that increase blood glucose and may necessitate higher insulin doses. - ACE inhibitors or ARBs in patients with renal impairment, as they can affect insulin sensitivity. - Thyroid hormones or levothyroxine therapy, as altered metabolic rate may modify insulin requirements.